GlassScriptPhysician profile
Aaron M Scheib
NPI 1689918666
$4,260.31
in general payments reported to CMS, 2019-2025
21 companies · $4,063 in 2025
The $4,063 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $122 · 2024: $75.14 · 2025: $4,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,260.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $626.99 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $540.33 | 2023-2025 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $482.83 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $434.69 | 2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $404.41 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $317.90 | 2024-2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $297.07 | 2025 | |
| Vanda Pharmaceuticals INC. | $196.25 | 2025 | Fanapt, Hetlioz |
| Corium, LLC | $196.11 | 2025 | Azstarys |
| Axsome Therapeutics, INC. | $183.25 | 2025 | Auvelity, Symbravo |
| Indivior INC. | $105.32 | 2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $97.95 | 2025 | Trintellix |
| Lundbeck LLC | $89.06 | 2025 | Rexulti |
| Tris Pharma INC | $79.46 | 2025 | Dyanavel Xr |
| Almatica Pharma LLC | $63.80 | 2025 | Loreev Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tms Neurohealth Centers INC. | $42.51 | 2025 | Tms Neurohealth Centers INC. |
| Collegium Pharmaceutical, INC. | $40.54 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $19.44 | 2024 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $15.35 | 2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $13.56 | 2025 | Relexxii |
| E.R. Squibb & Sons, L.L.C. | $13.49 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Scheib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.